Alpaslan Dedeoglu, MD, PhD

Alpaslan Dedeoglu

Associate Professor of Neurology
Director, Translational Neurotherapeutics Laboratory

Phone: 857.364.6783
Fax: 857.364.4540
Email: dedeoglu@bu.edu
Location: VA Boston Healthcare System, Research and Development Service Building 1A – (151), 150 S. Huntington Ave, Boston, MA, 02130

Background

Dr. Alpaslan Dedeoglu received his MD from the Istanbul University School of Medicine and completed a pharmacology program at the Marmara University in 1992.  During and after his pharmacology program he worked at the University of Arizona, Ohio State University, and Massachusetts General Hospital; he then joined Boston University in 2000.  Dr. Dedeoglu’s major research interests are neuroanatomy, neuropathology, and the neurochemistry of animal models of neurodegenerative disorders.  His labs are located at the Boston VA Medical Center.  Dr. Dedeoglu is the PI of several ongoing projects that are funded by the NIH, VA, and private foundations.

Research Interests

Dr. Dedeoglu’s research interests include the following: neuroanatomy, immunocytochemistry, histochemistry of the brain, neuropathological and neurochemical basis of neurological disorders, and animal models of neurological diseases. He also works with therapeutic trials in rodent models of neurodegenerative disorders.

Awards/Memberships

Dr. Dedeoglu has received various awards: Sandoz Pharmacology Science Award (1989), Eczacibasi Scientific Research and Medicine Encouragement Award (1992), Alzheimer’s Disease Core Center pilot award (2001-2002). “Therapeutic Strategies in a Mouse Model of AD”  Principal Investigator, Alzheimer’s Association New Investigator Award (2002-2004)” Anti-inflammatory Therapy in a Mouse Model of AD“  Principal Investigator, Merit Award (2004-2011) “Therapeutic Strategies in a Transgenic Model of AD”, Principal Investigator, R21 NIA (2005-2007), Integrated Neuroimaging and Pathology of Alzheimer Mice”, Principal Investigator, Merit Award (2005-2008) “Integrated neuroimaging and neuropathological study of exercise in ALS”

Dr. Dedeoglu is a member of the Boston Society of Neurology and Psychiatry and the Society for Neuroscience.

Recent Publications

For full list of publications click here

  1. Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, Dedeoglu A. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer’s disease. Sci Rep. 2016; 6:24939. PMID: 27117087.
    View in: PubMed
  2. Jenkins BG, Zhu A, Poutiainen P, Choi JK, Kil KE, Zhang Z, Kuruppu D, Aytan N, Dedeoglu A, Brownell AL. Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration. Neuropharmacology. 2016 Sep; 108:462-73. PMID: 26581500.
    View in: PubMed
  3. Choi JK, Carreras I, Aytan N, Jenkins-Sahlin E, Dedeoglu A, Jenkins BG. The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer’s disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res. 2014 Nov 24; 1590:85-96. PMID: 25301691.
    View in: PubMed
  4. Korkmaz OT, Aytan N, Carreras I, Choi JK, Kowall NW, Jenkins BG, Dedeoglu A. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2014 Apr 30; 566:286-91. PMID: 24637017.
    View in: PubMed
  5. Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern RA, Qiu WQ. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Mol Psychiatry. 2015 Feb; 20(2):252-62. PMID: 24614496.
    View in: PubMed
  6. Carreras I, McKee AC, Choi JK, Aytan N, Kowall NW, Jenkins BG, Dedeoglu A. R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer’s disease. Brain Res. 2013 Dec 6; 1541:115-27. PMID: 24161403.
    View in: PubMed
  7. Aytan N, Choi JK, Carreras I, Kowall NW, Jenkins BG, Dedeoglu A. Combination therapy in a transgenic model of Alzheimer’s disease. Exp Neurol. 2013 Dec; 250:228-38. PMID: 24120437.
    View in: PubMed
  8. Chen CD, Sloane JA, Li H, Aytan N, Giannaris EL, Zeldich E, Hinman JD, Dedeoglu A, Rosene DL, Bansal R, Luebke JI, Kuro-o M, Abraham CR. The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS. J Neurosci. 2013 Jan 30; 33(5):1927-39. PMID: 23365232.
    View in: PubMed
  9. Choi JK, Carreras I, Dedeoglu A, Jenkins BG. Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer’s disease mouse models. Neuropharmacology. 2010 Sep-Oct; 59(4-5):353-7. PMID: 20399219.
    View in: PubMed
  10. Choi JK, Dedeoglu A, Jenkins BG. Longitudinal monitoring of motor neuron circuitry in FALS rats using in-vivo phMRI. Neuroreport. 2010 Feb 17; 21(3):157-62. PMID: 20118741.
    View in: PubMed
  11. Carreras I, Yuruker S, Aytan N, Hossain L, Choi JK, Jenkins BG, Kowall NW, Dedeoglu A. Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res. 2010 Feb 8; 1313:192-201. PMID: 19968977.
    View in: PubMed
  12. Choi JK, Küstermann E, Dedeoglu A, Jenkins BG. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur J Neurosci. 2009 Dec; 30(11):2143-50. PMID: 19930399.
    View in: PubMed
  13. Choi JK, Jenkins BG, Carreras I, Kaymakcalan S, Cormier K, Kowall NW, Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol. 2010 Jun; 223(2):377-84. PMID: 19679126.
    View in: PubMed
  14. Aydin C, Aytan N, Mahon MJ, Tawfeek HA, Kowall NW, Dedeoglu A, Bastepe M. Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha). Endocrinology. 2009 Aug; 150(8):3567-75. PMID: 19423757.
    View in: PubMed
  15. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008 May 1; 1207:225-36. PMID: 18374906.
    View in: PubMed
  16. Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington’s disease R6/2 mice. J Neurosci. 2007 Nov 21; 27(47):12908-15. PMID: 18032664.
    View in: PubMed
  17. Choi JK, Dedeoglu A, Jenkins BG. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 2007 May; 20(3):216-37. PMID: 17451183.
    View in: PubMed
  18. Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington’s disease. J Neurochem. 2005 Oct; 95(2):553-62. PMID: 16135087.
    View in: PubMed
  19. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer’s amyloidogenesis. Exp Gerontol. 2004 Nov-Dec; 39(11-12):1641-9. PMID: 15582280.
    View in: PubMed
  20. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004 Jun 25; 1012(1-2):60-5. PMID: 15158161.
    View in: PubMed
  21. Brownell AL, Chen YI, Yu M, Wang X, Dedeoglu A, Cicchetti F, Jenkins BG, Beal MF. 3-Nitropropionic acid-induced neurotoxicity–assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. J Neurochem. 2004 Jun; 89(5):1206-14. PMID: 15147513.
    View in: PubMed
  22. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J Neurochem. 2003 Jun; 85(6):1359-67. PMID: 12787055.
    View in: PubMed
  23. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR, Deodoglu A. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4281-6. PMID: 12640146.
    View in: PubMed
  24. Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Néri C. Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington’s disease. Proc Natl Acad Sci U S A. 2003 Mar 4; 100(5):2712-7. PMID: 12604778.
    View in: PubMed
  25. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK. Huntington’s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis. 2002 Dec; 11(3):410-24. PMID: 12586550.
    View in: PubMed
  26. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci. 2002 Oct 15; 22(20):8942-50. PMID: 12388601.
    View in: PubMed
  27. Dedeoglu A, Ferrante RJ, Andreassen OA, Dillmann WH, Beal MF. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Exp Neurol. 2002 Jul; 176(1):262-5. PMID: 12093104.
    View in: PubMed
  28. Wendt S, Dedeoglu A, Speer O, Wallimann T, Beal MF, Andreassen OA. Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radic Biol Med. 2002 May 1; 32(9):920-6. PMID: 11978494.
    View in: PubMed
  29. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci. 2002 Mar 1; 22(5):1592-9. PMID: 11880489.
    View in: PubMed
  30. Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Cytochrome C and caspase-9 expression in Huntington’s disease. Neuromolecular Med. 2002; 1(3):183-95. PMID: 12095160.
    View in: PubMed
  31. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington’s disease. J Neurochem. 2001 Dec; 79(6):1246-9. PMID: 11752065.
    View in: PubMed
  32. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport. 2001 Oct 29; 12(15):3371-3. PMID: 11711888.
    View in: PubMed
  33. Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci. 2001 Aug; 17(1):89-96. PMID: 11665866.
    View in: PubMed
  34. Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol. 2001 Jul; 50(1):112-7. PMID: 11456300.
    View in: PubMed
  35. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis. 2001 Jun; 8(3):479-91. PMID: 11447996.
    View in: PubMed
  36. Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol. 2001 Apr; 168(2):419-24. PMID: 11259130.
    View in: PubMed
  37. Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001 Apr; 77(2):383-90. PMID: 11299300.
    View in: PubMed
  38. Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Exp Neurol. 2001 Apr; 168(2):356-63. PMID: 11259123.
    View in: PubMed
  39. Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp Neurol. 2001 Jan; 167(1):189-95. PMID: 11161607.
    View in: PubMed
  40. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000 Aug 3; 11(11):2491-3. PMID: 10943709.
    View in: PubMed